Alliance Clinical Network and Atlas Clinical Research Merge to Form National Clinical Trial Platform
核心洞察
Alliance Clinical Network (搜索) and Atlas Clinical Research (搜索) have completed a strategic merger, combining nearly 50 years of clinical research experience.
The combined organization expands its geographic footprint across seven states: Arizona, California, Florida, Nevada, New York, Pennsylvania, and Texas.
Therapeutic capabilities are strengthened across CNS, dermatology, gastroenterology, internal medicine, metabolic, pain, vaccines, and women's health.
Alliance Clinical Network (搜索) and Atlas Clinical Research (搜索) have announced the completion of a strategic merger, creating a larger clinical research organization with a combined network spanning seven states and nearly 50 years of industry experience. The partnership is designed to enhance clinical trial recruitment and execution capabilities while expanding the combined company's geographic footprint across Arizona, California, Florida, Nevada, New York, Pennsylvania, and Texas.
The merger brings together complementary expertise in clinical research and strengthens therapeutic capabilities across central nervous system (CNS) disorders, internal medicine, women's health, metabolic conditions, dermatology, gastroenterology, pain, and vaccines. The combined organization aims to deliver improved quality, collaboration, diversity, and operational excellence for pharmaceutical sponsors and contract research organization (CRO) partners.
"This partnership provides an opportunity for us to make a greater impact on the industry and its stakeholders," said Anthony Milonas, CEO of Alliance Clinical Network (搜索). "We believe we are positioned to excel as we focus on predictability, consistency and transparency, while delivering performance-driven results across our expanded clinical site network."
Atlas Clinical Research (搜索) CEO Mark Scullion added, "This merger significantly expands our geographic footprint and creates a national platform across key clinical research markets. Together, we are better positioned to support pharmaceutical sponsors navigating increasingly complex drug development requirements while maintaining the culture, responsiveness and standards that have defined both organizations."
Expanded Therapeutic Capabilities and Geographic Reach
By integrating their site networks, therapeutic expertise, and operational best practices, the companies expect to provide greater consistency, speed, and quality in clinical trial execution. The expanded platform will also improve patient recruitment efforts and increase access to diverse patient populations across multiple disease areas.
Key benefits of the merger include expanded therapeutic expertise across CNS, dermatology, gastroenterology, internal medicine, metabolic, pain, vaccines, and women's health; broader geographic coverage with research sites across seven states; enhanced patient recruitment capabilities and access to diverse populations; and strengthened operational excellence through aligned centers of excellence and standardized best practices.
Leadership and Financial Backing
Following the transaction, the combined company will be led by Anthony Milonas as CEO and will maintain its headquarters in Southlake, Texas. The organization will continue to receive support from healthcare-focused private equity firms Amulet Capital Partners (搜索) and BPOC (搜索).
Amulet Capital Partners (搜索), based in Greenwich, CT, and Walnut Creek, CA, is a middle-market private equity investment firm focused exclusively on the healthcare sector. The firm currently manages approximately $2.5 billion of Regulatory Assets Under Management and is investing out of its third fund, which closed in July 2024 with approximately $1.2 billion in capital commitments.
BPOC (搜索), founded in 1996 and based in Chicago, is one of the nation's longest-tenured pure-play investors in the healthcare industry, having raised seven funds with total capital commitments of approximately $2.5 billion. The firm has invested in numerous provider, manufacturing, outsourcing, distribution, and information technology companies through growth equity, management buyouts, and leveraged recapitalizations.
The combined organization is positioned to deliver greater consistency, speed, and quality for sponsors and CRO partners nationwide, supporting pharmaceutical sponsors as they navigate increasingly complex drug development requirements.